| 13.58 -0.42 (-3%) | 04-25 16:00 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term |  |
|||
| Targets | 6-month : | 19.53 | 1-year : | 23.73 |
| Resists | First : | 16.72 | Second : | 20.31 |
| Pivot price | 14.75 |
|||
| Supports | First : | 10.92 | Second : | 9.08 |
| MAs | MA(5) : | 13.35  |
MA(20) : | 15.44 |
| MA(100) : | 21.2 |
MA(250) : | 28.17 |
|
| MACD | MACD : | -1.7 |
Signal : | -1.7 |
| %K %D | K(14,3) : | 40.3 |
D(3) : | 35.2 |
| RSI | RSI(14): 31.8 |
|||
| 52-week | High : | 59.99 | Low : | 10.92 |
Price has closed above its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BEARISH in mid-long term.[ SAGE ] has closed above bottom band by 30.9%. Bollinger Bands are 44.1% wider than normal. The large width of the bands suggest high volatility as compared to its normal range. The bands have been in this wide range for 6 days. This is a sign that the current trend might continue.
| If tomorrow: | Open lower | Open higher |
| High: | 14.99 - 15.07 | 15.07 - 15.13 |
| Low: | 13.39 - 13.47 | 13.47 - 13.54 |
| Close: | 13.44 - 13.58 | 13.58 - 13.7 |
Sage Therapeutics, Inc., a biopharmaceutical company, develops and commercializes medicines to treat central nervous system disorders. Its lead product candidate is ZULRESSO, an intravenous formulation of brexanolone for the treatment of postpartum depression (PPD) in adults. The company's product pipeline also includes zuranolone, a neuroactive steroid, which is in Phase III clinical trials for treating PPD, major depressive disorders, treatment resistant disorders, generalized anxiety disorders, and bipolar depression; and SAGE-324, a compound that is in Phase II clinical trial to treat essential tremors, as well as has completed Phase I clinical trial for epilepsy and Parkinson's diseases. In addition, its product pipeline comprises SAGE-718, an oxysterol-based positive allosteric modulator of the NMDA receptor, which has completed Phase I clinical trial for the treatment of depression, Huntington's disease, Alzheimer's disease, attention deficit hyperactivity disorder, schizophrenia, and neuropathic pain. Sage Therapeutics, Inc. has a strategic collaboration with Shionogi & Co., Ltd. for the development and commercialization of zuranolone in Japan, Taiwan, and South Korea; and a collaboration and license agreement with Biogen MA Inc. to jointly develop and commercialize SAGE-217 and SAGE-324 products. The company was formerly known as Sterogen Biopharma, Inc. and changed its name to Sage Therapeutics, Inc. in September 2011. Sage Therapeutics, Inc. was incorporated in 2010 and is headquartered in Cambridge, Massachusetts.
Thu, 25 Apr 2024
Sage Therapeutics, Inc. (SAGE) Reports Q1 Loss, Tops Revenue Estimates - Zacks Investment Research
Thu, 25 Apr 2024
Sage Therapeutics Announces First Quarter 2024 Financial Results and Highlights Pipeline and Business Progress - Business Wire
Wed, 24 Apr 2024
Sage Therapeutics Q1 2024 Earnings Preview (NASDAQ:SAGE) - Seeking Alpha
Fri, 19 Apr 2024
SAGE Therapeutics Adjusts Inducement Equity Plan and Sets End Date - TipRanks.com - TipRanks
Wed, 17 Apr 2024
Sage Therapeutics’ stock plunges as Parkinson’s drug trial disappoints - MarketWatch
Mon, 15 Apr 2024
Sage Therapeutics Blocks Broad 'SageForth' Trademark Application - Bloomberg Law
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Neutral |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Underperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 0 (M) |
| Shares Float | 60 (M) |
| Held by Insiders | 4.755e+007 (%) |
| Held by Institutions | 12.5 (%) |
| Shares Short | 7,910 (K) |
| Shares Short P.Month | 0 (K) |
| EPS | -5.4507e+008 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 0 |
| Profit Margin | 0 % |
| Operating Margin | -54.3 % |
| Return on Assets (ttm) | -30.6 % |
| Return on Equity (ttm) | -52.8 % |
| Qtrly Rev. Growth | 2 % |
| Gross Profit (p.s.) | 731.17 |
| Sales Per Share | 1.01706e+008 |
| EBITDA (p.s.) | 0 |
| Qtrly Earnings Growth | -9.1 % |
| Operating Cash Flow | 0 (M) |
| Levered Free Cash Flow | -541 (M) |
| PE Ratio | -0.01 |
| PEG Ratio | -0.2 |
| Price to Book value | 0 |
| Price to Sales | 0 |
| Price to Cash Flow | 0.86 |
| Dividend | 0 |
| Forward Dividend | 8.6e+006 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|